The Risk Factors project has studied the very large HIV epidemic among injecting drug users (IDUs) in New York City from 1978 (using stored sera) and the very large HIV epidemic among non-injecting heroin and cocaine drug users (NIDUs) since 1995. In our current research, we have demonstrated a dramatic reduction in HIV transmission among IDUs, but also a substantial increase in HIV among NIDUS. (HIV prevalence has doubled among NIDUs in NYC over the last decade). Herpes simplex virus-2 (HSV-2) is strongly associated with HIV transmission, and we have identified prevalence HSV-2 as a major factor associated with HIV transmission among NIDUs in NYC.
The specific aims of the proposed research include: 1) Monitoring risk behavior, HIV prevalence and incidence and service utilization in the continuing evolution of the HIV epidemic among NIDUs and IDUs in New York City. 2) Quantifying the long-term population-level relationships between HIV and HSV-2 infections among heroin and cocaine users in NYC, including testing the hypothesis that the strength of the association between HSV-2 and HIV increases over time. Recent intervention studies have dramatically increased the need for understanding HSV-2/HIV relationships. 3) Evaluating effects of the New York City Department of Health (NYC DOH) Condom Social Marketing campaign on sexual risk behaviors and HIV and HSV-2 infection among IDUs and NIDUs in NYC. 4) Monitoring patterns of sexual and injection related HIV transmission among IDUs in NYC. There are many linkages between NIDUs and IDUs in NYC. NIDUs and IDUs are best viewed as linked groups within a single population of heroin and cocaine users in NYC. A thorough understanding of sexual transmission among NIDUs requires an understanding of both injecting and sexual transmission among IDUs in the city. 5) Assess new patterns of racial/ethnic differences in HIV infection among NIDUs and IDUs. 6) Intervention development.
These aims will be accomplished through continuation of our studies of NIDUs and IDUs entering Beth Israel drug treatment programs in NYC. The proposed research will be the first study of the spread of HIV over time in a very large population of NIDUs, the first assessment of change in the relationship of HVS-2 to HIV over time among NIDUs, and the first assessment of the effects of a very large condom social marketing campaign on sexual risk behavior of NIDUs and IDUs.

Public Health Relevance

Sexual transmission of HIV among non-injecting drug users has become a major public health problem in the US. This study will generate an in-depth understanding of the largest HIV epidemic among NIDUs in the US.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003574-30
Application #
8459511
Study Section
Behavioral and Social Consequences of HIV/AIDS Study Section (BSCH)
Program Officer
Hartsock, Peter
Project Start
1994-09-10
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
30
Fiscal Year
2013
Total Cost
$619,905
Indirect Cost
$218,187
Name
Beth Israel Medical Center (New York)
Department
Type
DUNS #
075255364
City
New York
State
NY
Country
United States
Zip Code
10003
Des Jarlais, Don C; Arasteh, K; Feelemyer, J et al. (2018) Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use. Drug Alcohol Depend 192:74-79
Des Jarlais, Don C; McKnight, Courtney; Feelemyer, Jonathan et al. (2018) Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001-2005 and 2011-2015. Drug Alcohol Depend 185:391-397
Campbell, Aimee N C; Wolff, Margaret; Weaver, Laurel et al. (2018) ""It's Never Just About the HIV:"" HIV Primary Care Providers' Perception of Substance Use in the Era of ""Universal"" Antiretroviral Medication Treatment. AIDS Behav 22:1006-1017
Des Jarlais, D C; Cooper, H L F; Arasteh, K et al. (2018) Potential geographic ""hotspots"" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US. PLoS One 13:e0194799
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit et al. (2018) Association of IFN?4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. J Med Virol 90:1779-1783
Elliott, Jennifer C; Hasin, Deborah S; Des Jarlais, Don C (2017) Perceived health and alcohol use in individuals with HIV and Hepatitis C who use drugs. Addict Behav 72:21-26
Jõgeda, Ene-Ly; Huik, Kristi; Pauskar, Merit et al. (2017) Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe. J Med Virol 89:632-638
Des Jarlais, Don C (2017) Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J 14:51
Des Jarlais, Don C; Arasteh, Kamyar; Feelemyer, Jonathan et al. (2017) Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus. Sex Transm Dis 44:85-90
Des Jarlais, Don C; Arasteh, Kamyar; McKnight, Courtney et al. (2017) What happened to the HIV epidemic among non-injecting drug users in New York City? Addiction 112:290-298

Showing the most recent 10 out of 139 publications